CANSINOBIO announced the initiation of Phase I/II clinical trials for the CS-2036 VLP vaccine. This vaccine is a novel virus-like particle (VLP) vaccine designed to provide preventive protection against specific diseases. This clinical trial marks an important advancement for the company in the VLP vaccine technology platform. The clinical trial will assess the safety, tolerability, and immunogenicity of CS-2036. Dr. Yu Xiaofeng, the company's CEO, stated that this trial will provide critical data for the further development of CS-2036. The trial is expected to continue until its completion on December 20, 2024. CANSINOBIO hopes to lay the groundwork for potential future commercialization of the vaccine through this trial.

CANSINOBIO announced the initiation of Phase I/II clinical trials for the CS-2036 VLP vaccine. This vaccine is a novel virus-like particle (VLP) vaccine designed to provide preventive protection against specific diseases. This clinical trial marks an important advancement for the company in the VLP vaccine technology platform. The clinical trial will assess the safety, tolerability, and immunogenicity of CS-2036. Dr. Yu Xiaofeng, the company's CEO, stated that this trial will provide critical data for the further development of CS-2036. The trial is expected to continue until its completion on December 20, 2024. CANSINOBIO hopes to lay the groundwork for potential future commercialization of the vaccine through this trial.